270 related articles for article (PubMed ID: 29291931)
1. Mucus-penetrating solid lipid nanoparticles for the treatment of cystic fibrosis: Proof of concept, challenges and pitfalls.
Nafee N; Forier K; Braeckmans K; Schneider M
Eur J Pharm Biopharm; 2018 Mar; 124():125-137. PubMed ID: 29291931
[TBL] [Abstract][Full Text] [Related]
2. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors.
Nafee N; Husari A; Maurer CK; Lu C; de Rossi C; Steinbach A; Hartmann RW; Lehr CM; Schneider M
J Control Release; 2014 Oct; 192():131-40. PubMed ID: 24997276
[TBL] [Abstract][Full Text] [Related]
3. Rapid transport of muco-inert nanoparticles in cystic fibrosis sputum treated with N-acetyl cysteine.
Suk JS; Lai SK; Boylan NJ; Dawson MR; Boyle MP; Hanes J
Nanomedicine (Lond); 2011 Feb; 6(2):365-75. PubMed ID: 21385138
[TBL] [Abstract][Full Text] [Related]
4. Ciprofloxacin-loaded PLGA nanoparticles against cystic fibrosis P. aeruginosa lung infections.
Günday Türeli N; Torge A; Juntke J; Schwarz BC; Schneider-Daum N; Türeli AE; Lehr CM; Schneider M
Eur J Pharm Biopharm; 2017 Aug; 117():363-371. PubMed ID: 28476373
[TBL] [Abstract][Full Text] [Related]
5. Enhanced viscoelasticity of human cystic fibrotic sputum correlates with increasing microheterogeneity in particle transport.
Dawson M; Wirtz D; Hanes J
J Biol Chem; 2003 Dec; 278(50):50393-401. PubMed ID: 13679362
[TBL] [Abstract][Full Text] [Related]
6. Mucus, phlegm, and sputum in cystic fibrosis.
Rubin BK
Respir Care; 2009 Jun; 54(6):726-32; discussion 732. PubMed ID: 19467160
[TBL] [Abstract][Full Text] [Related]
7. Influence of electrolyte and poloxamer 188 on the aggregation kinetics of solid lipid nanoparticles (SLNs).
Wei CC; Ge ZQ
Drug Dev Ind Pharm; 2012 Sep; 38(9):1084-9. PubMed ID: 22181005
[TBL] [Abstract][Full Text] [Related]
8. Effect of chest physiotherapy on cystic fibrosis sputum nanostructure: an experimental and theoretical approach.
Abrami M; Maschio M; Conese M; Confalonieri M; Salton F; Gerin F; Dapas B; Farra R; Adrover A; Milcovich G; Fornasier C; Biasin A; Grassi M; Grassi G
Drug Deliv Transl Res; 2022 Aug; 12(8):1943-1958. PubMed ID: 35286625
[TBL] [Abstract][Full Text] [Related]
9. Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation.
Hussain A; Samad A; Singh SK; Ahsan MN; Haque MW; Faruk A; Ahmed FJ
Drug Deliv; 2016; 23(2):642-47. PubMed ID: 25013957
[TBL] [Abstract][Full Text] [Related]
10. Mucus permeating carriers: formulation and characterization of highly densely charged nanoparticles.
Pereira de Sousa I; Steiner C; Schmutzler M; Wilcox MD; Veldhuis GJ; Pearson JP; Huck CW; Salvenmoser W; Bernkop-Schnürch A
Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):273-9. PubMed ID: 25576256
[TBL] [Abstract][Full Text] [Related]
11. Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?
Conte G; Costabile G; Baldassi D; Rondelli V; Bassi R; Colombo D; Linardos G; Fiscarelli EV; Sorrentino R; Miro A; Quaglia F; Brocca P; d'Angelo I; Merkel OM; Ungaro F
ACS Appl Mater Interfaces; 2022 Feb; 14(6):7565-7578. PubMed ID: 35107987
[TBL] [Abstract][Full Text] [Related]
12. MUC5AC and MUC5B Mucins Are Decreased in Cystic Fibrosis Airway Secretions.
Henke MO; Renner A; Huber RM; Seeds MC; Rubin BK
Am J Respir Cell Mol Biol; 2004 Jul; 31(1):86-91. PubMed ID: 14988081
[TBL] [Abstract][Full Text] [Related]
13. Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology.
Li Y; Abbaspour MR; Grootendorst PV; Rauth AM; Wu XY
Eur J Pharm Biopharm; 2015 Aug; 94():170-9. PubMed ID: 25986587
[TBL] [Abstract][Full Text] [Related]
14. Nanoparticle penetration of human cervicovaginal mucus: the effect of polyvinyl alcohol.
Yang M; Lai SK; Yu T; Wang YY; Happe C; Zhong W; Zhang M; Anonuevo A; Fridley C; Hung A; Fu J; Hanes J
J Control Release; 2014 Oct; 192():202-8. PubMed ID: 25090196
[TBL] [Abstract][Full Text] [Related]
15. Modelling the bronchial barrier in pulmonary drug delivery: A human bronchial epithelial cell line supplemented with human tracheal mucus.
Murgia X; Yasar H; Carvalho-Wodarz C; Loretz B; Gordon S; Schwarzkopf K; Schaefer U; Lehr CM
Eur J Pharm Biopharm; 2017 Sep; 118():79-88. PubMed ID: 28373109
[TBL] [Abstract][Full Text] [Related]
16. Design and evaluation of itraconazole loaded solid lipid nanoparticulate system for improving the antifungal therapy.
Mukherjee S; Ray S; Thakur RS
Pak J Pharm Sci; 2009 Apr; 22(2):131-8. PubMed ID: 19339221
[TBL] [Abstract][Full Text] [Related]
17. Mucus penetrating properties of soft, distensible lipid nanocapsules.
Chen H; Mansfield EDH; Woods A; Khutoryanskiy VV; Forbes B; Jones SA
Eur J Pharm Biopharm; 2019 Jun; 139():76-84. PubMed ID: 30818012
[TBL] [Abstract][Full Text] [Related]
18. Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics.
Broughton-Head VJ; Smith JR; Shur J; Shute JK
Pulm Pharmacol Ther; 2007; 20(6):708-17. PubMed ID: 17055310
[TBL] [Abstract][Full Text] [Related]
19. Effect of mucoadhesive polymers on the in vitro performance of insulin-loaded silica nanoparticles: Interactions with mucin and biomembrane models.
Andreani T; Miziara L; Lorenzón EN; de Souza AL; Kiill CP; Fangueiro JF; Garcia ML; Gremião PD; Silva AM; Souto EB
Eur J Pharm Biopharm; 2015 Jun; 93():118-26. PubMed ID: 25843239
[TBL] [Abstract][Full Text] [Related]
20. Lipid-based mucus penetrating nanoparticles and their biophysical interactions with pulmonary mucus layer.
Alp G; Aydogan N
Eur J Pharm Biopharm; 2020 Apr; 149():45-57. PubMed ID: 32014491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
